Ro revenue, valuation & funding | Sacra
Ro
Telehealth marketplace for online doctor visits and prescription delivery for men’s health
Revenue
$598.00M
2024
Valuation
$7.00B
2025
Funding
$1.00B
2025
Growth Rate (y/y)
66%
2025
Details
Headquarters
New York, United States
CEO
Zachariah Reitano
Website
ro.co
Milestones
Founding Year
2017
Overview
Revenue
Ro Data Summary | Sacra
Annualized Revenue & Growth
$598.0M ↑ 66.1%YoY
Source: Sacra
Updated: Apr 13, 2026
Ro's annualized revenue in 2024 was $598M, showing a rise of 66% YoY from $360M in 2023. This growth was driven primarily by the successful launch of Ro Body, a GLP-1–centered obesity management business.
Previously, Ro's revenue was significantly contributed by the Ro man division, addressing erectile dysfunction and men’s health, accounting for ~60% of total revenue in 2021. However, by the end of 2024, the contribution from sexual health is estimated to be roughly ⅓ of total revenue.
In contrast, GLP-1 obesity management has seen substantial growth, expanding from about 3% of total revenue in 2021 to around 40% by the end of 2024. This category has become the main source of incremental revenue growth. In 2024, GLP-1 sales alone generated approximately $370M, supported by monthly care subscriptions and pharmacy economics.
Valuation & Funding
Valuation & Amount Raised
$7.0B
↑ $1.2B Total Raised
Source: Sacra
Updated: Apr 13, 2026
Ro completed its most recent funding round in February 2022, raising $150M, leading to a valuation of $7B, an increase from $5B in March 2021, and bringing total funding to $1.0B.
Valuation & Funding History
| Date | Event | Valuation | Amount | Price | Status | |
|---|---|---|---|---|---|---|
| Feb 2022 | Follow On | $7.0B | $150.0M | — | Closed | |
| Mar 2021 | Series D | — | — | — | Closed | |
| Jul 2020 | Series C | — | — | — | Closed | |
| Jul 2020 | Series C | — | — | — | Closed | |
| Apr 2019 | Series B | — | — | — | Closed | |
| Sep 2018 | Series A | — | — | — | Closed | |
| Oct 2017 | Seed | — | — | — | Closed |
Product
Ro’s journey began in 2017 with a focus on understanding the telehealth adoption process. Initial offerings catered to patients with high-intent conditions requiring discretion and convenience. Ro shifted the dynamics of patient-doctor interactions, allowing patients to begin with an online intake, which is reviewed asynchronously by clinicians, enabling ongoing communication through various mediums.
GLP-1 and Obesity Management
Ro's operations highlight direct collaborations with Novo Nordisk, allowing for affordable access to GLP-1 medications like Wegovy, positioning Ro effectively in the growing obesity treatment market. Additional offerings include oral GLP-1 medications and various other therapeutic solutions.
Competition
- Direct-to-Consumer Telehealth Clinics: Other telehealth companies like Hims & Hers replicate Ro's business model, starting from high-intent categories and expanding into related services.
- Platform Telehealth Incumbents: Large companies serving traditional health systems maintain valuable scales that Ro must contend with.
- Retail Healthcare: Retail chains provide bundled services that integrate telehealth into broader consumer platforms.
Risks
- Manufacturer Dependency: Relationships with pharmaceutical companies like Novo Nordisk could shift unexpectedly, affecting Ro's business model.
- GLP-1 Supply Volatility: Regulatory changes might impact the availability of weight-loss medications.
- Brand Investment Returns: Elevated spending on marketing without corresponding revenue growth could compress margins.
News
- January 30, 2026 - Ro secures $75M in Series C funding at a valuation of $1B to disrupt healthcare payments.
- January 28, 2026 - Launches Super Bowl ad campaign to promote GLP-1s aiming to reshape consumer perceptions.
- January 13, 2026 - Partners with Amgen to enhance GLP-1 access, positioning in a lucrative market.